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Correction to: British Journal of Cancer (2011) 104, 948–956;
doi:10.1038/bjc.2011.54
When published originally, earlier this year in Volume 104, the
authors noticed a couple of errors in the Results section.
The first is in the subheading entitled ‘Selection of peptide- and
ET-specific T cells’. In the second paragraph of this subsection, on
page 951, the second sentence should read ‘For example, of the
T cells initially specifically selected with the CHM1
319/HLA-
A*0201-multimer, 96 cell lines were grown and tested for specific
IFN-g release against CHM1
319 peptide.’
The legend of Figure 4 should read ‘Low granzyme B responses
against HLA class I blocked A673 and HLA-A*0201
þ PBMC
compared with unblocked A673.’
The publishers and authors are now happy to correct these
errors.
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Figure 4 Low granzyme B responses against HLA class I blocked A673 and HLA-A*0201
þ PBMC compared with unblocked A673. HLA class I blocking
before granzyme B ELISpots caused reversion of specific recognition by CHM1
319 or EZH2
666 peptide specific CD8
þ T cells at an effector to target (E/T)
ratio of 5:1. Granzyme B release upon contact with irradiated OKT3-stimulated/unstimulated HLA-A*0201
þ PBMC remained low compared with
unblocked A673 at the same E/T ratio. Asterisks indicate significance levels of A673 lysis compared with respective controls (two-tailed t-test, *Po0.05;
**Po0.01).
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